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Background: Steroid resistant nephrotic syndrome is a severe hereditary disease often caused by mutations in the
NPHS2 gene. This gene encodes the lipid binding protein podocin which localizes to the slit diaphragm of
podocytes and is essential for the maintenance of an intact glomerular filtration barrier. Podocin is a hairpin-like
membrane-associated protein that multimerizes to recruit lipids of the plasma membrane. Recent evidence
suggested that podocin may exist in a canonical, well-studied large isoform and an ill-defined short isoform.
Conclusive proof of the presence of this new podocin protein in the human system is still lacking.
Methods: We used database analyses to identify organisms for which an alternative splice variant has been
annotated. Mass spectrometry was employed to prove the presence of the shorter isoform of podocin in human
kidney lysates. Immunofluorescence, sucrose density gradient fractionation and PNGase-F assays were used to
characterize this short isoform of human podocin.
Results: Mass spectrometry revealed the existence of the short isoform of human podocin on protein level. We
cloned the coding sequence from a human kidney cDNA library and showed that the expressed short variant was
retained in the endoplasmic reticulum while still associating with detergent-resistant membrane fractions in sucrose
gradient density centrifugation. The protein is partially N-glycosylated which implies the presence of a
transmembranous form of the short isoform.
Conclusions: A second isoform of human podocin is expressed in the kidney. This isoform lacks part of the PHB domain.
It can be detected on protein level. Distinct subcellular localization suggests a physiological role for this isoform which may
be different from the well-studied canonical variant. Possibly, the short isoform influences lipid and protein composition of
the slit diaphragm complex by sequestration of lipid and protein interactors into the endoplasmic reticulum.
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Podocin, the protein encoded by the NPHS2 gene, is
mutated in hereditary steroid-resistant nephrotic syn-
drome (SRNS) and essential for an intact kidney filtra-
tion barrier [1-3]. Podocin is expressed at the glomerular
slit diaphragm in kidney podocytes, the visceral epithe-
lial cells of the kidney filtration barrier. Knock-out mice
have been shown to lack slit diaphragm and die within
the first weeks of life due to kidney failure [3]. Human* Correspondence: martin.hoehne@uk-koeln.de
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reproduction in any medium, provided the orpodocin consists of 383 amino acids and is predicted to
form a hairpin-like structure within the inner leaflet of
the plasma membrane lipid bilayer. A central PHB-
domain and two palmitoylated residues enable podocin to
recruit cholesterol [4]. Podocin’s function is currently
understood as a scaffold providing the necessary protein-
lipid microenvironment needed for proper function and
signaling of the slit diaphragm protein complex [4,5]. The
amino acid sequence is strongly conserved with approxi-
mately 86% identity between mouse and human homo-
logues. Database searches and recent publications have
suggested the presence of a shorter 315 amino acid iso-
form of human podocin that lacks one exon encoding the
central part of the PHB-domain (Figure 1) [6,7]. However, alltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
























Figure 1 Schematic overview and alignment of the podocin short isoform. A) Schematic drawing of podocin with the difference between
the two isoforms indicated. A major part of the PHB domain is missing in the short isoform. B) Sequence alignment of both human podocin
isoforms, Podcanon and Podshort. [UniProt:Q9NP85, UniProt:Q9NP85-2]. The PHB domain and the palmitoylated residues are indicated.
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tion and RT-PCR, making it uncertain whether the protein
is actually expressed. This is particularly interesting with re-
gard to the importance of a functional PHB domain. Here
we show that the short isoform is expressed in human kid-
neys and localizes to the endoplasmic reticulum raising the
intriguing hypothesis that podocin may serve distinct func-
tions in different parts of the podocyte.
Methods
Reagents and plasmids
The short isoform of human podocin was cloned with a
nested PCR approach from a human kidney cDNA library.The first primer set is binding in the 5′ and 3′-UTR, re-
spectively, and the second primer set is amplifying the
ORF and adds cloning sites to the PCR construct
(underlined in primer sequence). Primer sequences: hPod-




was cloned into a modified pcDNA6 expression vector
which adds a V5-tag or a FLAG-tag, respectively, to the
N-terminus of the expressed protein. To eliminate the pu-
tative N-glycosylation site at aa position 287 of the short
isoform, a modified QuikChange site directed mutagenesis
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hPod_NtoS_fp: ctgaattgcctgtcttctccgagctccagaactcagggaag
cctc and hPod_NtoS_rp: gaggcttccctgagttctggagctcggagaa
gacaggcaattcag. All constructs were verified by sequencing.
The following IP buffer was used for cell lysis: 1% Triton
X-100; 20 mM Tris pH 7.5; 25 mM NaCl; 50 mM NaF;
15 mM Na4P2O7; 1 mM EDTA; 0.25 mM PMSF; 5 mM
Na3VO4.
Antibodies were obtained from Sigma (anti podocin
#P0372), Serotec (anti V5 mAB #MCA1360), Millipore
(anti V5 pAb #AB3792), and Santa Cruz (anti Flotillin-
2 #sc-28320; anti-CD71/Transferrin receptor #sc-65882).
Cell culture and transfection
HEK 293 T and HeLa cells were cultured in DMEM
supplemented with 10% fetal bovine serum under stand-
ard conditions (5% CO2, 37°C). For transfection experi-
ments, cells were grown to 60–80% confluency and
transfected with plasmid DNA using the calcium phos-
phate method for HEK 293 T cells, or GeneJuice
(Novagen) for HeLa cells according to the manufac-
turer’s instructions.
Coimmunoprecipitation
Cells were incubated for 24 h after transfection, washed
with PBS, lysed in ice-cold IP-buffer (see above) on ice
for 15 Min and centrifuged (18.000 rpm, 4°C, 15 Min).
Supernatants containing equal amounts of total proteins
were incubated for 1 h at 4°C with M2 anti-FLAG agar-
ose beads (Sigma). The beads were washed three times
with IP-buffer and bound proteins were resolved by 10%
SDS-PAGE.
MS sample preparation
Human glomerular samples were prepared from healthy
kidney tissue of tumor nephrectomies by a sieving tech-
nique described elsewhere [9]. The study protocol was
approved by the independent ethics committee of Co-
logne University and all patients provided written in-
formed consent.
Human glomerular samples were denatured by boiling
in Lämmli buffer for 5 minutes, and unsoluble compo-
nents pelleted by centrifugation. Soluble protein content
was separated by standard SDS-Page gel electrophoresis
(4-20% Gradient gel) and stained with colloidal Coomassie
brilliant blue dye. Gel segments at the molecular weight
expected for the podocin protein (canonical isoform:
42.2 kDa; short isoform: 34.4 kDa) were excised from the
gel and subjected to mass spectrometry.
Peptide isolation and mass spectrometry
Tryptic in-gel digest
Following electrophoresis the gel was washed thoroughly
in water. The area of interest was cut out and mincedusing a scalpel. After destaining with 50% 10 mM
NH4HCO3/50% ACN at 55°C and dehydration in 100%
ACN gel pieces were equilibrated with 10 mM NH4HCO3
containing porcine trypsin (12.5 ng/μl; Promega) on ice
for 4 hours. Excess trypsin solution was removed and
tryptic hydrolysis was performed for 4 hours at 37°C in
10 mM NH4HCO3. The supernatant was collected and
further extraction steps were performed. After acidifica-
tion with 5% TFA, gel pieces were extracted twice with 1%
TFA and then with 60% ACN/40%H2O/0.1% TFA
followed by a subsequent two-step treatment using
100% ACN. The supernatant and the extractions were
combined and concentrated using a SpeedVac concen-
trator (Christ). Prior to nano-LC-MS/MS analysis the
peptides were desalted using STAGE Tip C18 spin col-
umns (Proxeon/Thermo Scientific) as described else-
where [10]. Eluted peptides were concentrated in
vacuo and then re-suspended in 0.5% acetic acid in
water to a final volume of 10 μl.
Nano-LC ESI-MS/MS mass spectrometry
Experiments were performed on a LTQ Orbitrap Discov-
ery mass spectrometer (Thermo Scientific) that was
coupled to an EASY-nLC nano-LC system (Proxeon/
Thermo Scientific). Intact peptides were detected in the
Orbitrap at 30,000 resolution in the mass-to-charge (m/z)
range 350–2000. Internal calibration was performed using
the ion signal of (Si(CH3)2O)6H at m/z 445.12003 as a
lock mass. For LC-MS/MS analysis, up to five CID spectra
were acquired following each full scan. Aliquots of the
samples were separated on a 15 cm, 75 μm reversed phase
column (Proxeon/Thermo Scientific). The gradient used
for liquid chromatography is described elsewhere in more
detail [11].
Peptide and protein identification
The search algorithm Sequest as implemented in the
Proteome Discoverer software (Thermo Scientific) was
used for protein identification. To identify the proteins
contained in the excised gel area, MS/MS data were
searched using the canonical sequence database of the
Homo sapiens reference proteome provided by the
UniProt Consortium using the target-decoy strategy.
The sequence of the predicted short isoform of podocin
was added to the database. The maximum of two modi-
fication was allowed per peptide. Oxidation of methio-
nine residues was used as a variable modification and
carbamidomethylation of cysteine residues as a fixed
modification. For Orbitrap data, 10 ppm mass tolerance
was allowed for intact peptide masses and 0.8 Da for
CID fragment ions detected in the linear ion trap. Peptides
were subsequently filtered to match a FDR < 0.01. Protein
identifications were based on at least 2 peptides. Ion chro-
matograms were extracted using the NHLBI in-house
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identified peptides [12]. Isotope patterns were visualized
using the MaxQuant Viewer software [13].
Lipid raft preparation
The preparation of detergent resistant membrane domains
(DRMs) was performed as described [14]. Briefly, HEK
293 T cells were homogenized in 1 ml lysis buffer
(150 mM NaCl; 20 mM Tris/HCl pH 7.4; 0.1 mM EDTA;
1% Triton X-100; 5 mM Na3VO4; 0.25 mM PMSF) by 20
strokes in a Dounce homogenizer. After centrifugation for
10 Min at 3.000 rpm at 4°C (Eppendorf F45-30-10 rotor),
supernatants containing equal amounts of total proteins
were carefully adjusted to 45% sucrose (1.6 ml final vol-
ume) and pipetted at the bottom of an ultracentrifuge
tube. Samples were then overlayed with 1.6 ml 30% and
0.8 ml 5% sucrose (in 150 mM NaCl; 20 mM Tris/HCl
pH 7.4; 0.1 mM EDTA) to create a sucrose gradient. Sam-
ples were centrifuged for 16 h at 41.000 rpm at 4°C in a
swing-out rotor (SW60Ti, Beckman Instruments), and
seven fractions were collected starting from top and
analysed by SDS-PAGE.
Immunofluorescence
Hela cells grown on a coverslip were transfected using
GeneJuice (Novagen). After 24 hours, cells were fixed in
4% paraformaldehyd in PBS for 15 minutes and blocked
with 5% normal donkey serum for 1 hour. Permeablization
was achieved by adding 0.2% Triton-X to the blocking so-
lution. Cells were then incubated with primary anti-
body directed against V5-tag for 45 minutes at room
temperature, washed extensively with PBS, and incu-
bated with fluorophore-coupled secondary antibody
for 45 min. Cells were mounted using ProlongGold
(Invitrogen) and imaged with a Zeiss LSM710 confocal
microscope equipped with a 63x/1.4 oil immersion
objective.
Results and discussion
Recently, it was suggested that the kidney disease pro-
tein podocin may exist in two isoforms that differ in size
[6,7]. Whereas the larger canonical isoform (Podcanon)
has been studied in detail, almost nothing is known
about a shorter version of the protein (Podshort). To
characterize this putative new isoform, we used database
searches and found that the isoform corresponding to
the short human isoform of podocin is also predicted in
several other species all belonging to the order of pri-
mates. However, these primate non-canonical isoforms
were predicted based on the presence of the human sug-
gested isoform, and no cDNA or EST clones supporting
the existence of these isoforms could be found in the da-
tabases. Since intron/exon boundaries are conserved be-
tween mouse and human, we speculated that a similarmurine short isoform existed, yet no such EST could be
found in our database searches. Moreover, several strat-
egies to clone the short splice variant from mouse kid-
ney and glomerulus cDNA libraries were not successful
[data not shown]. Thus, we focused on the confirmation
and identification of the short podocin isoform in hu-
man samples based on the predicted sequence of this
isoform.
To analyze the existence of the human short isoform
further, we intended to demonstrate the presence of the
shorter isoform on protein level using a mass spectro-
metric approach. To identify Podshort, we aimed to de-
tect a peptide spanning the border between exon 4 and
exon 6 as such a peptide would not be present in the ca-
nonical variant (Figure 2A). One crucial limitation of
mass spectrometry based identification in human glom-
erular samples is the low purity of a preparation using
the classical sieving technique as well as the limited
amount of starting material. We therefore used lysates
of HEK293T cells transfected with the canonical and
short podocin isoform, respectively, as reference sam-
ples. These samples were processed in parallel to the
glomerular sample and analyzed by mass spectrometry
subsequent to the glomerular lysates as described in the
method section.
Within the sample containing the short isoform of
podocin, we unambiguously identified the isoform-specific
peptide with the sequence LQTLEIPFHEVALDSVTcIWGIK.
This triple-charged peptide carried a carbamidomethylation
at the cysteine residue (m/z = 890.47). The MS2 spectrum
for this peptide is depicted in Figure 2B.
Next, we analyzed whether the specific mass correspond-
ing to this isoform-specific peptide (+/−10 ppm) was also
found within a very limited time window (+/− 1 min) in
the MS1 precursor chromatogram of the glomerular sam-
ple or the sample obtained from HEK cells expressing the
canonical podocin isoform. As expected, the peptide mass
was absent in the sample obtained from HEK293T cells
transfected with the canonical isoform whereas many other
peptides matching to podocin were by far more abundant
in this sample. However, the mass corresponding to the
short isoform specific peptide was also found in the human
glomerular sample (Figure 2C). In addition, the MS1 pre-
cursor isotope pattern confirmed the presence of a triple
charged peptide mass within both samples (Figure 2D).
Combining these results, we report evidence on protein
level for the existence of a shorter isoform of human
podocin.
To elucidate protein function, we cloned Podshort from a
human kidney cDNA library (Figure 3A). The canonical
isoform of podocin exerts its function at the slit diaphragm
protein/lipid complex at the plasma membrane. We there-
fore tested protein localization of Podshort. Overexpression
in HeLa cells and subsequent immunofluorescence staining
Figure 2 (See legend on next page.)
Völker et al. BMC Nephrology 2013, 14:102 Page 5 of 8
http://www.biomedcentral.com/1471-2369/14/102
(See figure on previous page.)
Figure 2 Mass spectrometry proves the presence of the podocin short isoform in human kidney. A) Schematic representation of the
intron/exon structure of podocin and the resulting protein. The shorter isoform lacks exon 5. To prove the existence of the shorter isoform, we
searched for a unique peptide expressed from the joined ends of exon 4 and 6. Tryptic peptides extracted from a SDS-PAGE gel area
corresponding to the shorter isoform of podocin were analysed by nanoLC-ESI-MS/MS. B) MS2 spectrum of the isoform specific peptide with the
sequence LQTLEIPFHEVALDSVTcIWGIK (m/z = 890.47). (The non-capitalized letter “c” denotes carbamidomethylation). The peptide was
unambiguously identified in protein digest of HEK 293 T cells expressing the short isoform. C) Extracted ion chromatogram of the MS1 precursor
masses of the isoform specific peptide from human glomeruli, and HEK293T cells transfected with the canonical or the short podocin isoform at
the time of peptide identification. The chromatogram reveals the presence of the same mass in human glomeruli at a very similar elution time
(m/z = 890.47). D) MS1 isotope pattern of the respective mass of the HEK293T sample transfected with the short isoform. The isotope pattern is
consistent with a triply charged peptide.
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plasmic reticulum and did not traffic to the plasma mem-
brane (Figure 3B). Interestingly, many mutants of the
canocial isform are also retained in the endoplasmic
reticulum [15]. A second level of targeting occurs with the
recruitment of podocin into detergent resistant mem-
branes, which is defective in a variety of mutants [14]. WeFigure 3 The podocin short isoform is retained in the ER and is
found in the detergent resistant membrane fraction. A) PCR
with podocin specific primers yields products for both isoforms from
a human kidney cDNA library. B) Immunofluorescence staining of
the canonical and the short isoform in Hela cells transfected with
the corresponding constructs show that only the canonical isoform
reaches the plasma membrane (arrowhead in the enlarged part of
the image). The short isoform is retained in the endoplasmic
reticulum. Scale bar = 10 μm. C) DRM association of both podocin
isoforms. HEK293T cells expressing the respective V5-tagged
podocin isoform were lysed in 1% TX-100 on ice and subjected to
sucrose density gradient centrifugation. Fractions 1–7 were collected
from the top and analyzed by Western blot. Both isoforms
fractionate into the DRMs (fractions 1 and 2, as identified by flotillin
staining). Antibodies against the transferrin receptor (TfR) and
Flotillin-2 were used as markers for the Triton soluble and insoluble
fractions, respectively.used sucrose density gradient ultracentrifugation to test if
the short isoform fractionated into the detergent resistant
membrane fraction (DRM). Contrary to the differences
seen in subcellular localization, both podocin isoforms
similarly localized to DRMs (Figure 3C), thus indicating
that the cholesterol recruiting property was not
compromised. Due to its interaction with several other slit
diaphragm proteins and its localization to detergent resist-
ant membranes, podocin is a central organizer of the slit
diaphragm protein complex [5,16]. We examined the inter-
action of the Podshort with several known slit diaphragm
interactors in co-immunoprecipitation experiments. Des-
pite the fact that the short isoform has a different subcellu-
lar distribution, we could not observe any difference
between the interaction of the canonical and the short
podocin isoform with CD2AP, TRPC6, NEPH1 and nephrin
(Figure 4).
Lystes from cells transfected with Podshort, showed a
prominent double band in Western blots (Figure 3C,
fractions 5–7; Figure 4). We hypothesized that a part of
the protein pool was post-translationally modified.
One possible form of post-translational modification is
N-glycosylation. For stomatin, another PHB-domain
protein, point mutations have recently been identified that
change the membrane topology to a transmembranous
form with N-glycosylation occurring at the extracellular
part [17]. The N-glycosylation of stomatin led to a well-
detectable double band in western blots very similarly to
the double band we observed with Podshort. We therefore
tested next if the additional western blot band of the
podocin short-isoform was the result of N-glycosylation.
Treatment of lysates with PNGase-F, an enzyme that se-
lectively removes N-glycosyl sugar chains, abrogated the
second band in Western blot experiments (Figure 5A).
To validate this finding further, we mutated the single
N-glycosylation consensus motif (N-X-S/T, where X is
any amino acid, except for proline) in the podocin
short isoform (N287S [aa 355 in the canonical iso-
form]). Mutation of this motif from NRT to SRT com-
pletely prevented the occurrence of a second band in
Western blots (Figure 5B), hence confirming our hypothesis
that the observed double band was due to N-glycosylation
of Podshort. It is interesting to note that deleting parts of the
Figure 4 The podocin short isoform interacts with known podocyte proteins. CD2AP, TRPC6, neprin and NEPH1 co-precipitate with both
podocin isoforms (FL, full length (canoncical isoform); SI, short isoform). FLAG- and V5-tagged proteins were expressed in HEK293T cells and
precipitated with anti-FLAG antibody as indicated. Western blot analysis was performed with a V5 specific antibody. Expression levels of FLAG.
podocin constructs in the lysates are shown below.
Figure 5 The podocin short isoform is N-glycosylated.
A) PNGase-F treatment removes the double band from the short
isoform in DRM fraction 7. Lysates from Figure 3 were subjected to
treatment with PNGase-F and immunoblotted and detected with
anti-V5 antibody. B) N to S mutation of the N-glycosylation
consensus motif completely abrogates the formation of a double
band. The asparagine at position 287 corresponds to amino acid 355
in the full-length protein. HEK293T cells were transfected with V5-
tagged Podocin (short isoform or short isoform N287S, respectively)
and lysates were immunoblotted and detected with
anti-V5 antibody.
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the protein membrane topology as a single point mutation
in a region preceding the PHB domain as in stomatinP47S. It
has been shown that also in wildtype stomatin, the forma-
tion of the hairpin loop protein was not 100% efficient and
that a certain pool of the wildtype protein was also N-
glycosylated [17]. Because of the low abundance compared
with the hairpin loop form, a physiological function for the
transmembranous form was considered rather unlikely [17].
For Podshort, it seems that a considerable fraction is
glycosylated and hence present in the non-hairpin loop con-
formation. However, the functional implication of these ob-
servations and the physiological role of Podshort remains to
be elucidated.
Conclusions
Here we provide evidence for a human podocin splice
variant that lacks exon 5. This splice variant is translated
into protein but does not reach the plasma membrane in
detectable amounts. The canonical isoform of human
podocin has been studied extensively: It recruits a
multimeric protein supercomplex – the slit diaphragm
protein complex – to cholesterol-rich fractions of the
plasma membrane thus providing the microenvironment
needed for proper function of associated cation-channels
and signaling at the slit-diaphragm. Since we did not
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form from any other species, except from human, we
wondered whether this isoform is transcribed and trans-
lated in humans and can be identified on protein level.
Previous reports have indicated the presence of a protein
corresponding to this isoform [6,7]. However these ana-
lyses were based on antibody techniques which can be
difficult to interpret from complex samples such as
glomerular lysates. We therefore used mass spectrom-
etry to unambiguously confirm the presence of this short
podocin isofrom in human glomerular lysates. This iso-
form still interacts with known interaction partners and,
like the canonical isoform, partitions into detergent re-
sistant membranes. However, it does not localize to the
plasma membrane, but this naturally occurring variant is
retained in the endoplasmic reticulum, a phenotype pre-
viously known from many podocin mutants. Interest-
ingly, almost half of the short-isoform protein appeared
to be N-glycosylated at an asparagine residue close to
the C-terminus. This indicates that at least parts of the
short isoform podocin shows a transmembranous con-
formation with the C-terminus facing towards the lumen
of the endoplasmic reticulum. However, the functional
implications of these findings remain elusive. It is an in-
teresting observation that there is no database evidence
based on ESTs or cDNAs for any other species indicative
of the existence of this short isoform. Most likely the
lack of such evidence in the primate species that have
this isoform predicted is due to the lack of EST data.
However, for other species as for example mouse or rat
there is plenty of EST and cDNA data available. Yet this
particular isoform cannot be found although intron/exon
boundaries for exon 5 are conserverved. This may indi-
cate that the described short isoform of podocin is spe-
cific to primates and missing in rodents.
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